-transparent.png){kind=logo}
The effect of mergocryptine, a new ergot alkaloid, on the cerebral dopaminergic systems was examined using Wistar rats. The administration of mergocryptine (1 and 10 mg/kg i.p.) induced a significant suppression of striatal dopamine (DA) turnover. In vitro addition of mergocryptine (0.01-100 microM) induced a dose-dependent suppression of the release of [3H]DA from striatal slices. Mergocryptine inhibited [3H]apomorphine binding to a striatal synaptosomal fraction, and its IC50 value was found to be 0.23 microM. Pretreatment with apomorphine (100 micrograms/kg s.c.) showed an additive effect on the mergocryptine (10 mg/kg)-induced suppression of DA turnover. These results suggest that mergocryptine may induce the suppression of striatal DA turnover by reducing DA release via the stimulation of presynaptic dopaminergic autoreceptors.
T Hashimoto, and
M Katsura, and
K Kuriyama
January 1980,
Farmakologiia i toksikologiia,
T Hashimoto, and
M Katsura, and
K Kuriyama
January 1975,
Acta biologica et medica Germanica,
T Hashimoto, and
M Katsura, and
K Kuriyama
June 1975,
The Journal of pharmacy and pharmacology,
T Hashimoto, and
M Katsura, and
K Kuriyama
December 1985,
Brain research,
T Hashimoto, and
M Katsura, and
K Kuriyama
June 1984,
Proceedings of the National Academy of Sciences of the United States of America,
T Hashimoto, and
M Katsura, and
K Kuriyama
August 1986,
European journal of pharmacology,
T Hashimoto, and
M Katsura, and
K Kuriyama
November 1984,
European journal of pharmacology,
T Hashimoto, and
M Katsura, and
K Kuriyama
June 1989,
European journal of pharmacology,
T Hashimoto, and
M Katsura, and
K Kuriyama
March 1985,
Journal of neurochemistry,
T Hashimoto, and
M Katsura, and
K Kuriyama
September 1987,
Journal of neurochemistry,
